Literature DB >> 17875181

HLA-DQB1 0602 allele is associated with splenomegaly in Japanese sarcoidosis.

H Sato1, S Nagai, R M du Bois, T Handa, Y Suginoshita, K Ohta, K I Welsh, T Izumi.   

Abstract

OBJECTIVES: The association between HLA class II alleles and susceptibility to sarcoidosis is well documented. Further, the HLA-DRB1 15 and DQB1 0602 haplotype has been considered as a marker for both chronic and severe disease. Splenomegaly has been proposed as a marker for severity and activity in sarcoidosis, although its functional mechanism is unknown. In other diseases, HLA class II alleles can be markers for splenomegaly. We therefore set out to test the hypothesis that the primary DRB1 15-DQB1 0602 link in sarcoidosis would be to splenomegaly. DESIGN AND
SUBJECTS: We performed abdominal ultrasonography to evaluate the prevalence and extent of splenomegaly and genotyped for HLA-DRB1 and DQB1 using allele or allele group specific primers in polymerase-chain-reaction on 138 Japanese sarcoidosis patients as case comparison study. Furthermore, we explored their relationship with other clinically important indices, e.g. chest radiograph stage, serum angiotensin-converting enzyme (ACE) concentration and duration of disease.
RESULTS: Splenomegaly was detected in 37 (26.8%) sarcoidosis patients. DQB1 0602 showed associations with splenomegaly (P < 0.0001) and longer disease duration (P = 0.007). In addition, higher chest radiograph staging was associated with both DQB1 0602 (P = 0.02) and splenomegaly (P = 0.003). The presence of splenomegaly was associated with higher serum ACE concentration (P < 0.0001).
CONCLUSION: We conclude that in the Japanese population the primary association of HLA class II DQB1 0602 is with splenomegaly. This allele is also a marker for chronicity and lung disease severity. On the other hand, the presence of splenomegaly is a marker for severity and activity. Further studies are needed to explore the relationship between splenomegaly and sarcoidosis in other ethnic groups and its association with HLA-DQB1 0602.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875181     DOI: 10.1111/j.1365-2796.2007.01829.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

1.  Early prediction of sarcoidosis prognosis with HLA typing: a 5 year follow-up study.

Authors:  Ezgi Ozyilmaz; Ozlem Goruroglu Ozturk; Ali Durmaz; Orhan Othman Hasan; Bugra Guzelbaba; Gulsah Seydaoglu; Sedat Kuleci; Ismail Hanta; Eren Erken; Ali Kocabas
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

2.  Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups.

Authors:  Hiroe Sato; Felix A Woodhead; Tariq Ahmad; Jan C Grutters; Paolo Spagnolo; Jules M M van den Bosch; Lisa A Maier; Lee S Newman; Sonoko Nagai; Takateru Izumi; Athol U Wells; Roland M du Bois; Kenneth I Welsh
Journal:  Hum Mol Genet       Date:  2010-08-03       Impact factor: 6.150

Review 3.  Immunogenetics of Disease-Causing Inflammation in Sarcoidosis.

Authors:  Johan Grunewald; Paolo Spagnolo; Jan Wahlström; Anders Eklund
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

Review 4.  Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis.

Authors:  Pleiades T Inaoka; Masato Shono; Mishio Kamada; J Luis Espinoza
Journal:  J Biomed Sci       Date:  2019-06-11       Impact factor: 8.410

5.  Multisystemic Sarcoidosis Presenting With Leg Ulcers, Pancytopenia, and Polyserositis Was Successfully Treated With Glucocorticoids: A Case Report and Literature Review.

Authors:  Xin Qiao; Shan He; Abdullah Altawil; Qiu-Yue Wang; Jian Kang; Wen-Yang Li; Yan Yin
Journal:  Front Med (Lausanne)       Date:  2022-02-15

6.  Atypical Sarcoidosis Diagnosed by Massive Splenomegaly.

Authors:  Satomi Saito; Kazuhisa Kodama; Tomomi Kogiso; Yuki Yamanashi; Makiko Taniai; Shunichi Ariizumi; Masakazu Yamamoto; Katsutoshi Tokushige
Journal:  Intern Med       Date:  2019-10-31       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.